Pfizer Q3 Revenue Dips 6% Amid R&D Surge, Net Income Down 21%

Ticker: PFE · Form: 10-Q · Filed: 2025-11-04T00:00:00.000Z

Sentiment: mixed

Topics: Pharmaceuticals, Biotechnology, Earnings Report, R&D Spending, Revenue Decline, Net Income, COVID-19 Impact

Related Tickers: PFE, BNTX, ABBV, BMY, TAK

TL;DR

**Pfizer's Q3 is a mixed bag: short-term pain from revenue and profit dips, but big R&D spending hints at future growth if their pipeline delivers.**

AI Summary

Pfizer Inc. reported a decrease in total revenues for the three months ended September 28, 2025, falling to $16.654 billion from $17.702 billion in the prior year, a 6.0% decline. Product revenues specifically decreased by 9.7% from $15.417 billion to $13.920 billion. Net income attributable to Pfizer Inc. common shareholders also saw a significant drop, from $4.465 billion in Q3 2024 to $3.541 billion in Q3 2025, representing a 20.7% decrease. Diluted earnings per common share decreased from $0.78 to $0.62. Despite these declines, alliance revenues increased by 21.0% to $2.298 billion, and royalty revenues grew by 13.5% to $436 million. The company experienced a substantial increase in acquired in-process research and development expenses, rising from $13 million to $1.390 billion for the quarter, indicating significant R&D investments. For the nine months ended September 28, 2025, net income attributable to Pfizer Inc. common shareholders increased to $9.419 billion from $7.621 billion in the prior year, a 23.6% rise, primarily due to a tax benefit of $264 million compared to a $393 million tax provision in the prior year. Total assets decreased to $208.731 billion from $213.396 billion at December 31, 2024.

Why It Matters

Pfizer's Q3 revenue decline and significant drop in net income, despite a year-to-date net income increase, signal a challenging period for investors. The substantial increase in acquired in-process R&D expenses to $1.390 billion suggests aggressive pipeline investment, which could be a long-term positive but pressures short-term profitability. This competitive landscape, particularly with the decline in product revenues, highlights the need for successful new drug launches to offset expiring patents and reduced demand for COVID-19 related products like Paxlovid and Comirnaty. Employees might face pressure to deliver on these R&D investments, while customers could see new therapies emerge, albeit with potential pricing implications. The broader market will watch how Pfizer navigates this transition, impacting the pharmaceutical sector's innovation and growth outlook.

Risk Assessment

Risk Level: medium — The risk level is medium due to a 6.0% decline in total revenues and a 20.7% decrease in net income for the three months ended September 28, 2025, compared to the prior year. This is partially offset by a significant increase in acquired in-process R&D expenses to $1.390 billion, indicating substantial investment in future growth, which carries inherent development risks.

Analyst Insight

Investors should closely monitor Pfizer's upcoming pipeline developments and regulatory approvals, especially given the $1.390 billion in acquired in-process R&D expenses. While Q3 showed revenue and net income declines, the year-to-date net income increase and strategic R&D investments suggest a long-term growth strategy that requires patience and careful evaluation of future product launches.

Financial Highlights

revenue
$16.654B
total Assets
$208.731B
net Income
$3.541B
eps
$0.62
revenue Growth
-6.0%

Revenue Breakdown

SegmentRevenueGrowth
Product revenues$13.920B-9.7%
Alliance revenues$2.298B+21.0%
Royalty revenues$436M+13.5%

Key Numbers

Key Players & Entities

FAQ

What were Pfizer's total revenues for the third quarter of 2025?

Pfizer's total revenues for the three months ended September 28, 2025, were $16.654 billion, a decrease from $17.702 billion in the same period of 2024.

How did Pfizer's net income change in Q3 2025 compared to Q3 2024?

Net income attributable to Pfizer Inc. common shareholders decreased by 20.7% to $3.541 billion in Q3 2025, down from $4.465 billion in Q3 2024.

What was the impact of acquired in-process R&D expenses on Pfizer's Q3 2025 results?

Acquired in-process research and development expenses significantly increased to $1.390 billion in Q3 2025, compared to only $13 million in Q3 2024, indicating substantial investment in future pipeline assets.

Did Pfizer's year-to-date net income improve in 2025?

Yes, for the nine months ended September 28, 2025, net income attributable to Pfizer Inc. common shareholders increased to $9.419 billion, up from $7.621 billion in the prior year, a 23.6% rise.

What were Pfizer's diluted earnings per share for Q3 2025?

Pfizer's diluted earnings per common share for the three months ended September 28, 2025, were $0.62, a decrease from $0.78 in the same period of 2024.

How much cash did Pfizer generate from operating activities year-to-date in 2025?

For the nine months ended September 28, 2025, Pfizer generated $6.356 billion in net cash from operating activities, an increase from $6.023 billion in the prior year.

What is the current status of Paxlovid's approval by the FDA?

Paxlovid has not been approved but is authorized for emergency use by the FDA for mild-to-moderate COVID-19 in pediatric patients (12 years and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19.

What is Pfizer's fiscal quarter-end for its U.S. and non-U.S. subsidiaries?

Pfizer's fiscal quarter-end for U.S. subsidiaries is September 28, 2025, and for subsidiaries operating outside the U.S. is August 24, 2025.

How many shares of Pfizer's common stock were outstanding as of October 29, 2025?

As of October 29, 2025, 5,685,707,552 shares of Pfizer's voting common stock were outstanding.

What was the change in Pfizer's total assets from December 31, 2024, to September 28, 2025?

Pfizer's total assets decreased from $213.396 billion at December 31, 2024, to $208.731 billion at September 28, 2025.

Risk Factors

Industry Context

The pharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies like Pfizer compete on innovation, patent protection, and market access. Trends include a focus on biologics, personalized medicine, and strategic acquisitions to bolster pipelines. The market is also sensitive to global health trends, such as pandemic preparedness and the demand for vaccines.

Regulatory Implications

Pfizer operates under stringent regulations from bodies like the FDA and EMA, impacting drug approval, manufacturing, and marketing. Changes in healthcare policies, such as pricing regulations or government programs like the 340B Drug Pricing Program, can significantly affect revenue and profitability. Compliance with evolving data privacy and environmental regulations is also critical.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Acquired in-process research and development expenses
Costs incurred for research and development projects that have not yet reached technological feasibility and have no alternative future use. These are often expensed immediately. (A significant increase in these expenses ($1.390B in Q3 2025) indicates substantial investment in new drug development, impacting current period profitability.)
Alliance revenues
Revenue generated from agreements where Pfizer co-promotes products developed by other companies or where its own products are co-promoted by partners. (This revenue stream showed strong growth (+21.0%), offsetting some of the decline in product revenues.)
Diluted EPS
Earnings per share calculated by dividing net income by the weighted-average number of outstanding common shares, including the dilutive effect of stock options and convertible securities. (A key profitability metric for shareholders; it decreased from $0.78 to $0.62 in Q3 2025.)
Provision/(benefit) for taxes on income
The amount of income tax expense or benefit recognized for a period. (A significant shift from a tax provision of $393 million in YTD 2024 to a tax benefit of $264 million in YTD 2025 positively impacted net income for the nine-month period.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Pfizer Inc. reported a 6.0% decrease in total revenues for Q3 2025, driven by a 9.7% drop in product revenues. Net income also saw a significant decline of 20.7% in the quarter. However, alliance and royalty revenues showed robust growth, increasing by 21.0% and 13.5% respectively. A notable shift occurred in R&D expenses, with acquired in-process R&D expenses soaring from $13 million to $1.390 billion, indicating a strategic investment in future growth. For the nine months ended September 28, 2025, net income increased by 23.6%, largely due to a favorable tax benefit compared to a tax provision in the prior year. Total assets decreased slightly from the end of 2024.

Filing Stats: 4,619 words · 18 min read · ~15 pages · Grade level 14.1 · Accepted 2025-11-04 07:03:48

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Page Item 1.

Financial Statements

Financial Statements Condensed Consolidated Statements of Operations 5 Condensed Consolidated Statements of Comprehensive Income 6 Condensed Consolidated Balance Sheets 7 Condensed Consolidated Statements of Equity 8 Condensed Consolidated Statements of Cash Flows 9 Notes to Condensed Consolidated Financial Statements 10 Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 36 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 57 Item 4.

Controls and Procedures

Controls and Procedures 57

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 57 Item 1A.

Risk Factors

Risk Factors 57 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 58 Item 3. Defaults Upon Senior Securities N/A Item 4. Mine Safety Disclosures N/A Item 5. Other Information 58 Item 6 . Exhibits 58 Signature 58 N/A = Not Applicable 2 DEFINED TERMS Unless the context requires otherwise, references to "Pfizer," "the Company," "we," "us" or "our" in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer's fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 24, 2025 and August 25, 2024, and for U.S. subsidiaries is as of and for the three and nine months ended September 28, 2025 and September 29, 2024. References to "Notes" in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2024 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below: * Indicates calculation not meaningful or results are greater than 100% 2024 Form 10-K Annual Report on Form 10-K for the fiscal year ended December 31, 2024 340B Program 340B Drug Pricing Program 3SBio 3SBio, Inc. and its subsidiaries Shenyang Sunshine Pharmaceutical Co., Ltd. and 3S Guojian Pharmaceutical (Shanghai) Co., Ltd. AbbVie AbbVie Inc. Abingworth Abingworth LLP ACIP Advisory Committee on Immunization Practices AI artificial intelligence ALK anaplastic lymphoma kinase Alliance revenues Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us Astellas Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. ATTR-CM transthyretin amyloid cardiomyopathy BioNTech BioNTech SE Biopharma Global Biopharmaceuticals Business Blackstone Blackstone Life Sciences BMS Bristol-Myers Squibb Company BOD Board of Directors CDC U.S. Centers for Disease Control and Prevention CMS

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS PFIZER INC. AND SUBSIDIARY COMPANIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended Nine Months Ended (MILLIONS, EXCEPT PER SHARE DATA) September 28, 2025 September 29, 2024 September 28, 2025 September 29, 2024 Revenues: Product revenues $ 13,920 $ 15,417 $ 37,168 $ 38,731 Alliance revenues 2,298 1,900 6,684 6,140 Royalty revenues 436 384 1,170 992 Total revenues 16,654 17,702 45,022 45,864 Costs and expenses: Cost of sales (a) 4,172 5,263 10,795 11,942 Selling, informational and administrative expenses (a) 3,186 3,244 9,632 10,456 Research and development expenses (a) 2,546 2,598 7,231 7,787 Acquired in-process research and development expenses 1,390 13 1,401 20 Amortization of intangible assets 1,223 1,312 3,644 3,927 Restructuring charges and certain acquisition-related costs 286 313 945 1,669 Other (income)/deductions––net 517 243 2,210 2,030 Income from continuing operations before provision/(benefit) for taxes on income 3,334 4,715 9,162 8,033 Provision/(benefit) for taxes on income ( 216 ) 234 ( 264 ) 393 Income from continuing operations 3,550 4,481 9,427 7,640 Discontinued operations––net of tax — ( 8 ) 25 4 Net income before allocation to noncontrolling interests 3,550 4,473 9,452 7,644 Less: Net income attributable to noncontrolling interests 9 8 33 23 Net income attributable to Pfizer Inc. common shareholders $ 3,541 $ 4,465 $ 9,419 $ 7,621 Earnings per common share––basic : Income from continuing operations attributable to Pfizer Inc. common shareholders $ 0.62 $ 0.79 $ 1.66 $ 1.35 Discontinued operations––net of tax — — — — Net income attributable to Pfizer Inc. common shareholders $ 0.62 $ 0.79 $ 1.66 $ 1.35 Earnings per common share––diluted : Income from continuing operations attributable to Pfizer Inc. common shareholders $ 0.62 $ 0.79 $ 1.65 $ 1.34 Discontinued operations––net of tax — — — — Net income attributable to Pfizer Inc. common

View on Read The Filing